Nanomedicines for Endothelial Disorders

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The endothelium lines the internal surfaces of blood and lymphatic vessels and has a critical role in maintaining homeostasis. Endothelial dysfunction is involved in the pathology of many diseases and conditions, including disorders such as diabetes, cardiovascular diseases, and cancer. Given this common etiology in a range of diseases, medicines targeting an impaired endothelium can strengthen the arsenal of therapeutics. Nanomedicine – the application of nanotechnology to healthcare – presents novel opportunities and potential for the treatment of diseases associated with an impaired endothelium. This review discusses therapies currently available for the treatment of these disorders and highlights the application of nanomedicine for the therapy of these major disease complications.

Graphical Abstract

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 101297352

Journal ID (pubmed-jr-id): 36300

Journal ID (nlm-ta): Nano Today

Journal ID (iso-abbrev): Nano Today

Title: Nano today

ISSN (Print): 1748-0132

ISSN (Electronic): 1878-044X

Publication date Nihms-submitted: 23 December 2015

Publication date (Print): 1 December 2015

Publication date PMC-release: 01 December 2016

Volume: 10

Issue: 6

Pages: 759-776

Affiliations

[1 ]David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

[2 ]Department of Chemical Engineering, Massachusetts Institute of Technology

[3 ]George W. Woodruff School of Mechanical Engineering, Wallace H. Coulter Department of Biomedical Engineering, Institute for Electronics and Nanotechnology (IEN), Parker H. Petit Institute for Bioengineering and Bioscience (IBB), Georgia Institute of Technology

[4 ]Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital, Harvard Medical School

[5 ]Department of Biological Engineering, Massachusetts Institute of Technology

[6 ]Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology

[7 ]Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai

[8 ]King Abdulaziz University, Jeddah, Saudi Arabia

Author notes

[* ]Corresponding authors: Robert Langer, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Room 76-661, Cambridge, Massachusetts 02139-4307, (phone) 617-253-3107, (fax) 617-258-8827, rlanger@ 123456mit.edu , YongTae Kim, George W. Woodruff School of Mechanical Engineering, Wallace H. Coulter Department of Biomedical Engineering, Institute for Electronics and Nanotechnology (IEN), Parker H. Petit Institute for Bioengineering and Bioscience (IBB), Georgia Institute of Technology, 345 Ferst Drive (Rm 3134), Atlanta, GA 30332, (phone) 404-385-1478, (fax) 404-385-8535, ytkim@ 123456gatech.edu

[†]

Equally contributed

Article

Accession ID: PMC4778260 Pmcid ID: PMC4778260 Pmc-uid ID: 4778260 Manuscript ID: nihpa746052

DOI: 10.1016/j.nantod.2015.11.009

PMC ID: 4778260

PubMed ID: 26955397

SO-VID: 2972f343-3120-4532-82c4-bdb040964943

History

Comments

Comment on this article

scite_

Cited by 16

See all cited by

- Version 1
- Version 1